Bromodomain and extraterminal protein-targeted probe enables tumour visualisation in vivo using positron emission tomography.
Dickmann, C.G.F., McDonald, A.F., Huynh, N., Rigopoulos, A., Liu, Z., Guo, N., Osellame, L.D., Gorman, M.A., Parker, M.W., Gan, H.K., Scott, A.M., Ackermann, U., Burvenich, I.J.G., White, J.M.(2023) Chem Commun (Camb) 59: 3126-3129
- PubMed: 36809538 
- DOI: https://doi.org/10.1039/d2cc04813b
- Primary Citation of Related Structures:  
8DYR, 8E17, 8E3W - PubMed Abstract: 
Bromodomain and extraterminal (BET) proteins, a family of epigenetic regulators, have emerged as important oncology drug targets. BET proteins have not been targeted for molecular imaging of cancer. Here, we report the development of a novel molecule radiolabelled with positron emitting fluorine-18, [ 18 F]BiPET-2, and its in vitro and preclinical evaluation in glioblastoma models.
Organizational Affiliation: 
Bio21 Institute, The University of Melbourne, Parkville, VIC 3010, Australia. whitejm@unimelb.edu.au.